Keyphrases
6-mercaptopurine (6-MP)
33%
Acute Lymphoblastic Leukemia
100%
Ara-C
100%
Calla
33%
CD10
33%
Chemotherapy Dose
33%
Chromosome 11
33%
CNS Relapse
33%
CNS Therapy
33%
Complete Remission
33%
Consolidation Therapy
33%
Continuation Therapy
33%
Cyclophosphamide
33%
Cytosine Arabinoside
33%
Effective Therapy
33%
Event-free Survival
66%
Group Experiences
100%
Hydrocortisone
33%
Infant Acute Lymphoblastic Leukemia
100%
Intrathecal Drug Delivery
33%
Isolated CNS Relapse
33%
Lymphoblast
33%
Marrow
66%
Methotrexate
66%
Older children
33%
Outcome Improvement
33%
Pediatric Oncology
100%
Prednisone
33%
Previous Experience
33%
Radiotherapy
33%
Remission Induction
33%
Standard Triple
33%
Teniposide
33%
Therapeutic Trial
100%
Working Diagnosis
33%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
100%
Body Weight
25%
Chemotherapy
25%
Childhood Cancer
100%
Chromosome 11
25%
Combination Therapy
100%
Common Acute Lymphoblastic Leukemia Antigen
25%
Cyclophosphamide
25%
Cytarabine
100%
Event Free Survival
50%
Hydrocortisone
25%
Lymphoblast
25%
Mercaptopurine
25%
Methotrexate
50%
Prednisone
25%
Pulse Rate
25%
Radiation Therapy
25%
Spine
25%
Spontaneous Remission
25%
Teniposide
25%
Vincristine
25%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
100%
Chemotherapy
25%
Childhood Cancer
100%
Combination Therapy
100%
Common Acute Lymphoblastic Leukemia Antigen
25%
Cyclophosphamide
25%
Cytarabine
100%
Event Free Survival
50%
Hydrocortisone
25%
Intrathecal
25%
Mercaptopurine
25%
Methotrexate
50%
Prednisone
25%
Remission
50%
Teniposide
25%
Vincristine
25%
Immunology and Microbiology
Body Weight
50%
Chromosome 11
50%
Common Acute Lymphoblastic Leukemia Antigen
50%
Cortisol
50%
Cyclophosphamide
50%
Event Free Survival
100%
Lymphoblast
50%
Methotrexate
100%
Prednisone
50%
Pulse Rate
50%
Vertebral Column
50%